10:48 AM EST - Spectral Medical Inc. : Provided a corporate update on its Tigris trial, COVID-19 initiatives, EAA launch, and Dialco regulatory activities. As previously disclosed in the Company’s Corporate Update dated April 28, 2020, the Tigris trial recruitment activity slowed at the beginning of March 2020 due to the COVID-19 pandemic, with most trial site ICUs diverting their research resources and focus to treating COVID-19 positive patients. While several Tigris sites continued to screen and enroll patients throughout the pandemic, enrollment was lower than anticipated rates. As a result, the Tigris timeline has been negatively impacted with a delay of approximately three months. The Company anticipates a return to normalized recruitment levels, with all 10 sites indicating active screening status by mid-August. Spectral Medical Inc.
shares T.EDT are trading up $0.03 at $0.54.
